Clearline Capital’s Flexion Therapeutics, Inc. FLXN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-1,910,153
| Closed | -$11.7M | – | 201 |
|
|
2021
Q3 | $11.7M | Sell |
1,910,153
-213,546
| -10% | -$1.33M | 1.1% | 26 |
|
|
2021
Q2 | $17.5M | Buy |
2,123,699
+720,322
| +51% | +$6.13M | 2.6% | 9 |
|
|
2021
Q1 | $12.6M | Buy |
+1,403,377
| New | +$16.1M | 1.63% | 14 |
|
|
2020
Q4 | – | Sell |
-399,159
| Closed | -$4.16M | – | 109 |
|
|
2020
Q3 | $4.16M | Sell |
399,159
-126,574
| -24% | -$1.55M | 1.09% | 32 |
|
|
2020
Q2 | $6.91M | Buy |
+525,733
| New | +$5.45M | 2.25% | 18 |
|
|
2019
Q4 | – | Sell |
-797,987
| Closed | -$10.9M | – | 74 |
|
|
2019
Q3 | $10.9M | Sell |
797,987
-112,555
| -12% | -$1.34M | 4.98% | 3 |
|
|
2019
Q2 | $11.2M | Buy |
910,542
+353,832
| +64% | +$4.08M | 5.47% | 2 |
|
|
2019
Q1 | $6.95M | Buy |
556,710
+422,316
| +314% | +$5.64M | 3.63% | 9 |
|
|
2018
Q4 | $1.52M | Sell |
134,394
-256,682
| -66% | -$4.02M | 1.04% | 32 |
|
|
2018
Q3 | $7.32M | Buy |
391,076
+181,736
| +87% | +$4.18M | 4.33% | 6 |
|
|
2018
Q2 | $5.41M | Buy |
+209,340
| New | +$5.43M | 3.52% | 8 |
|
Clearline Capital's FLXN Position: Q4 2021 in Review
Clearline Capital sold out of Flexion Therapeutics, Inc. (FLXN) in Q4 2021, closing a stake of 1,910,153 shares — an estimated $11.7M sold.
Clearline Capital first reported a position in FLXN in Q2 2018 and held it in 11 quarters. The position peaked at $17.5M in Q2 2021. 1 fund tracked by Wall St. Rank holds FLXN as of Q4 2021.
- Clearline Capital reported no remaining Flexion Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
- Clearline Capital sold 1,910,153 Flexion Therapeutics, Inc. shares in Q4 2021, an estimated $11.7M.
- Clearline Capital first reported a position in Flexion Therapeutics, Inc. in Q2 2018 and held it in 11 quarters.
- Clearline Capital's Flexion Therapeutics, Inc. position peaked at $17.5M in Q2 2021.
- 1 fund tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q4 2021.
Based on Clearline Capital's 13F filing for Q4 2021, filed 14 Feb 2022.